US drug major Pfizer raised its adjusted earnings and revenue guidance for the full-year as it reported financial results for the third quarter on Tuesday. For fiscal 2024, the company now projects adjusted earnings in a range of $2.75 to $2.95 per share on revenues between $61 billion and $64 billion. Covid-19 vaccine Comirnaty is forecast to bring in $5 billion while Paxlovid, a Covid-19 treatment, is set to earn $5.5 billion. Previously, the company expected revenues between $59.5 billion and $62.5 billion. Including the contribution from cancer drug Seagen and excluding revenues from Comir…